Ritter Pharmaceuticals Inc., of Los Angeles, closed its private placement of series B convertible preferred stock and warrants for gross proceeds of about $6 million. Proceeds are expected to fund a phase III trial of RP-G28 for lactose intolerance, which is expected to complete in the second half of 2019.